SCHEMBL30786164

SCHEMBL30786164

C=Cc1ccn(CCCN2CCCC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.39
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HRH4 Q9H3N8 2/20 0.36
SIGMAR1 Q99720 2/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
THPO P40225 1/20 0.35
HIF1A Q16665 1/20 0.35
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LTA4H P09960 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6308796 0.76 EHMT2 (0.39) HRH3ALDH1A1HRH4SIGMAR1MEN1
SCHEMBL30786259 0.76 L3MBTL1 (0.41) HRH3ALDH1A1HRH4SIGMAR1CYP3A4
SCHEMBL6302511 0.74 HRH3 (0.41) HRH3ALDH1A1HRH4SIGMAR1CYP3A4
SCHEMBL22420062 0.74 NPC1 (0.38) KDM4EALDH1A1RAB9ACYP2D6LMNA
SCHEMBL6305135 0.72 ALDH1A1 (0.38) HRH3ALDH1A1HRH4SIGMAR1MEN1
SCHEMBL6308791 0.70 PARP1 (0.41) HRH3KDM4EALDH1A1HRH4MTOR
SCHEMBL30786071 0.69 HRH3 (0.39) HRH3KDM4EALDH1A1HRH4HRH1
SCHEMBL165242 0.69 PARP1 (0.43) HRH3KDM4EALDH1A1HRH4MTOR
SCHEMBL15412963 0.69 PKM (0.58) HRH3KDM4EALDH1A1CYP3A4CYP2D6
SCHEMBL12126122 0.68 HRH1 (0.53) HRH3KDM4EALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 HRH3 2004/4885KDM4E 3216/4885ALDH1A1 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.